FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response:	s)		_													
Name and Address of Reporting Person * Sherman Darren					2. Issuer Name and Ticker or Trading Symbol Motus GI Holdings, Inc. [MOTS]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director				
(Last) (First) (Middle) C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 02/06/2020								Officer (give	e title below)	Other_	(specify below)	
(Street) FT. LAUDERDALE,, FL 33301				4. If Am	4. If Amendment, Date Original Filed(Month/Day/Year)							_X_1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City	y)	(State)	(Zip)			Ta	ble I	- Non-	Deriva	tive Secu	rities	Acquired,	Disposed	of, or Bene	ficially Owned		
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)			2A. Deem Execution any (Month/De	Code (Inst	3. Transaction Code (Instr. 8)		4. Securities Acquire (A) or Disposed of (Instr. 3, 4 and 5) (A) or Amount (D) Pr		of (D	Benefic Reporte (Instr. 3	Reported Transaction(s) Instr. 3 and 4) Ownership Form: Direct (D) or Indirect (I) Ownership Form: Direct (D) or Indirect (I)		Benefici Ownersh ct (Instr. 4)	al iip			
Common \$0.0001 1	Stock, pa	r value	02/06/2020				A	V	12,50 (1)	_ ` ´	\$ C		(2)		(Instr. 4)		
Common Stock, par value \$0.0001 per share											2,000,	2,000,000		I		By Orchestra BioMed, Inc.	
Common Stock, par value \$0.0001 per share											51,498	51,498		I	By Accele Techno Inc. (4)		
Reminder:	Report on a s	separate line for ea	ach class of securitie	s beneficia	lly own	ed dire	ectly	Per in t	rsons this fo	rm are r	ot re		respond	unless the	tion containe e form	d SEC 14	74 (9-02)
			Table I							ed of, or ertible s		icially Own	ied				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A, Deemed Execution Date, rr) (Month/Day/Yea	4. Transac Code	5. tion of Se or or of (Ir	5. Number		6. Date Exercisable and Expiration Date (Month/Day/Year)		d	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security	Securities Beneficially Owned Following Reported Transaction(s)	Security: Direct (D) or Indirect (I)	11. Natur of Indirec Beneficia Ownershi (Instr. 4)	
				Code	v	(A)	(D)		isable l	Expiration Date	n	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option (right to buy)	\$ 2.16	02/06/2020		A	12	2,500		Ĺ	<u>5)</u> ()2/06/2	030	Common Stock, par value \$0.0001 per share	12,500	\$ 0	12,500 (2)	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Sherman Darren C/O MOTUS GI HOLDINGS, INC. 1301 EAST BROWARD BOULEVARD, 3RD FLOOR FT. LAUDERDALE,, FL 33301	X					

Signatures

/s/ Andrew Taylor, power of attorney	02/07/2020		
Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- On February 6, 2020, Reporting Person was granted 12,500 Common Stock restricted stock units. The restricted stock units vest as to 50% of the shares on February 6, 2021, and the (1) remaining restricted stock unit shares vest on February 6, 2022. Each restricted stock unit represents a contingent right to receive one share of Common Stock. The restricted stock units award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan").
 - In prior reports, Reporting Person reported indirect beneficial ownership of (A) 109,792 shares of Issuer Common Stock held by Orchestra Medical Ventures II, L.P. ("OMV II"), (B) a warrant to purchase 108,838 shares of Issuer Common Stock held by OMV II, (C) a warrant to purchase 106,980 shares of Issuer Common Stock held by Orchestra Medical Ventures II Reserve, L.P. ("OMV Reserve"), (E) 1,159,968 shares of Issuer Common Stock held by Orchestra MOTUS Co-Investment
- (2) Partners, LLC ("OMCP"), (F) a warrant to purchase 115,997 shares of Issuer Common Stock held by OMCP, and (G) a warrant to purchase 69,139 shares of Issuer Common Stock held by OMCP. Each of OMV II, OMV Reserve and OMCP distributed all of their securities of Issuer on a pro rata basis to their members, for no consideration, on 12/31/2019 and Reporting Person retained no direct or indirect beneficial ownership of any shares of Issuer Common Stock or warrants to purchase shares of Issuer Common Stock pursuant to such pro rata distributions
- Reporting Person is a member of the board of directors of Orchestra BioMed, Inc., a Delaware corporation ("OBIO"). Reporting Person jointly exercises dispositive and voting power (3) over the shares owned by OBIO. Reporting Person disclaims, for purposes of Section 16, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein, and this report shall not be deemed an admission that Reporting Person is the beneficial owners of such securities for purposes of Section 16 or for any other purposes.
- Reporting Person jointly exercises dispositive and voting power over the shares owned by Accelerated Technologies, Inc. ("ATI"). Reporting Person disclaims, for purposes of Section (4) 16, beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein, and this report shall not be deemed an admission that Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
- The option award was made in accordance with the terms of the 2016 Plan. The option becomes exercisable as to 50% of the shares on February 6, 2021, and the remaining shares will (5) become exercisable on February 6, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.